| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0961203313476154 |
| P698 | PubMed publication ID | 23553780 |
| P2093 | author name string | M Axelsson | |
| I Gunnarsson | |||
| I Parodis | |||
| P2860 | cites work | Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. | Q51966554 |
| Systemic lupus erythematosus. | Q53495545 | ||
| Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives | Q57089850 | ||
| TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 | ||
| Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS | Q24290135 | ||
| Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator | Q28183674 | ||
| BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF | Q28213294 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Understanding the epidemiology and progression of systemic lupus erythematosus | Q33621131 | ||
| Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts | Q34060110 | ||
| Belimumab: review of use in systemic lupus erythematosus | Q34215264 | ||
| Current and novel therapeutics in the treatment of systemic lupus erythematosus | Q34648851 | ||
| Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus | Q34802966 | ||
| BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. | Q35140484 | ||
| Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus | Q35555433 | ||
| Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients | Q35928031 | ||
| Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus | Q35954719 | ||
| Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response | Q36094045 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Systemic lupus erythematosus: modern strategies for management: a moving target | Q37027954 | ||
| Novel evidence-based systemic lupus erythematosus responder index | Q37356378 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 | ||
| Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases | Q37725436 | ||
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry | Q42661986 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide | Q46416350 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Combined oral contraceptives in women with systemic lupus erythematosus | Q46851436 | ||
| Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus | Q47913418 | ||
| P433 | issue | 4 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| belimumab | Q1996249 | ||
| P304 | page(s) | 372-380 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Belimumab for systemic lupus erythematosus: a practice-based view | |
| P478 | volume | 22 |
| Q26782454 | Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus |
| Q35008162 | Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy |
| Q30490276 | First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. |
| Q39953054 | Real life experience on the effect of Belimumab in patients with active systemic lupus |
| Q37272264 | Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices |
| Q51152275 | Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. |
| Q33411317 | Thrombocytopenia and thrombosis: a double-edged sword |
Search more.